Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$141.75 USD

141.75
681,591

+2.42 (1.74%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $141.98 +0.23 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

by Zacks Equity Research

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 17.39% and 3.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

by Zacks Equity Research

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Glaukos (GKOS) Stock Gains 0.1% Following Lower Loss in Q2

by Zacks Equity Research

Despite reporting second-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 54.17% and 9.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) is Oversold: Can It Recover?

by Zacks Equity Research

Glaukos (GKOS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

Glaukos (GKOS) Down 11.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Glaukos (GKOS) owing to its strategic alliances and a strong iStent product line.

Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1

by Zacks Equity Research

Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of 30.00% and 4.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Glaukos (GKOS) Down 7.1% Since Last Earnings Report?

by Zacks Equity Research

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Glaukos (GKOS) Stock Right Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

    Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Glaukos' (GKOS) fourth-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

    Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Glaukos (GKOS) delivered earnings and revenue surprises of 93.75% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Glaukos (GKOS) Up 24.3% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.